Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction
Conditions
Gastric Cancer
Conditions: official terms
Adenocarcinoma - Stomach Neoplasms
Conditions: Keywords
Gastric Cancer, capecitabine, maintenance treatment
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Capecitabine Type: Drug
Name: capecitabine Type: Drug
Overall Status
Recruiting
Summary
The purpose of this study is to investigate whether Taxanes or Platinum Plus Capecitabine With Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer is effective and safe.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Having signed informed consent

2. Age≥ 18 years old

3. Histologically confirmed gastric adenocarcinoma

4. Unresectable recurrent or metastatic disease

5. Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 6 months

6. Previous chemotherapy with oxaliplatin or cisplatin or paclitaxel or docetaxel, if applicable, more than 12 months.

7. Measurable disease according to the RECIST criteria

8. ECOG performance status ≤2

9. Life expectancy of ≥3 month

10. No prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks

11. ALT and AST≤2.5 times ULN (≤5 times ULN in patients with liver metastases) Serum albumin level ≥3.0g/dL Serum creatinine ≤1.5ULN Bilirubin level ≤ 1.5 ULN WBC>3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet>90,000/mm3, Hb>8g/dl

Exclusion Criteria:

1. Brain metastasis (known or suspected)

2. Previous systemic therapy for metastatic gastric cancer

3. Inability to take oral medication

4. Previous therapy targeting at angiogenesis or vasculogenesis pathway or other targeted therapy

5. Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry

6. Allergic constitution or allergic history to any investigating agents.

7. Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.

8. Pregnancy or lactation period

9. Any investigational agent within the past 28 days

10. Other previous malignancy within 5 year

11. Pre-existing neuropathy>grade 1

12. Legal incapacity
Location
307 Hospital of PLA
Beijing, Beijing, China
Status: Recruiting
Contact: Xu jianming, M.D. - 86-10-66947176 - jmxu2003@yahoo.com
Start Date
November 2011
Completion Date
June 2013
Sponsors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Source
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page